Amsterdam-based digital health company Flouria Health has raised new funding from Dutch health tech investor Healthy.Capital, bringing its total funding to €1.5 million as it prepares to expand its women’s hormonal healthcare platform across Europe.
Announced on 1 October 2026, the investment will support Flouria’s continued growth in the Netherlands and help prepare the company for entry into additional European markets.
Founded to address gaps in women’s healthcare, Flouria operates a digital clinic providing access to specialist doctors, testing, personalised treatment plans and ongoing clinical support. Its care model currently focuses on areas including perimenopause, postpartum recovery and PCOS.
Rather than limiting care to individual consultations, the company aims to provide continuity from diagnosis and treatment through follow-up.
Building a Digital Clinic for Women’s Hormonal Health
Flouria was founded in 2024 by Jeanine van Munster, Vlatko Stojovski and Anna Christie.
Van Munster serves as Chief Executive Officer, Stojovski as Chief Technology Officer and Christie as Chief Commercial Officer. The leadership team is supported by medical leads Lotte van Dijk and Jolijn Huisman.
The founders say their own experiences with women’s healthcare helped shape the company. Flouria’s founders have spoken about experiences involving fertility, pregnancy loss, postpartum care and premature menopause, which contributed to their decision to build a different model of care.
The company describes its proposition as a full-lifecycle digital women’s health clinic, designed to support women through different phases of their health journey.
Its platform gives patients the ability to select a relevant care pathway, arrange an intake and receive care from specialised doctors online.
More Than 1,000 Women Served
Flouria launched its consumer health proposition in October 2025.
According to the company, it has since provided hormonal healthcare to more than 1,000 women in the Netherlands.
The new investment gives Flouria additional capital to continue developing its Dutch operation while laying the foundations for expansion into other European markets.
The company is positioning its model around greater access to specialised care and longer-term clinical support, areas where patients can face delays in conventional healthcare systems.
Its approach combines a network of specialist doctors with digital delivery, allowing consultations, testing, treatment planning and follow-up to take place through the platform.
Healthy.Capital Backs Women’s Health Access
Healthy.Capital, a Dutch health tech venture capital firm, made the latest investment.
The investor said Flouria represents an opportunity to improve access to specialised women’s healthcare while making more effective use of limited healthcare capacity.
The investment also reflects a wider focus from health tech investors on women’s healthcare, particularly areas where diagnosis and access to specialist treatment remain limited.
For Flouria, the funding is intended to support growth rather than simply expand the company’s technology platform. Its stated ambition is to establish itself as a leading women’s hormonal health provider in Europe.
From Perimenopause to Postpartum Care
Hormonal health covers a broad range of conditions and life stages, and Flouria’s current care proposition reflects that.
The company supports women dealing with perimenopause, postpartum recovery and PCOS, alongside other women’s health needs.
Its model is based on combining specialist medical care with digital access, allowing women to receive personalised treatment and follow-up without relying solely on short, one-off consultations.
This is particularly relevant to hormonal health, where symptoms can evolve over time and patients may require adjustments to treatment and continued clinical support.
Flouria’s approach is therefore built around a longer-term relationship between patient and healthcare provider.
Preparing for European Expansion
The Netherlands remains Flouria’s home market, but the new funding is intended to support preparations for expansion beyond the country.
The company has not yet disclosed which European markets it plans to enter first.
Its expansion strategy will come as digital women’s health companies continue to develop services around areas that have historically received less attention within mainstream healthcare.
For Flouria, the immediate focus is on demonstrating that its digital clinic model can provide accessible, specialist-led care at scale.
The company says its ambition is to become a leading provider of women’s hormonal healthcare in Europe.
